Previous close | 89.70 |
Open | 89.29 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 92.96 - 95.07 |
52-week range | 84.53 - 119.56 |
Volume | |
Avg. volume | 63,990 |
Market cap | N/A |
Beta (5Y monthly) | 0.38 |
PE ratio (TTM) | 0.16 |
EPS (TTM) | 5.59 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RAHWAY, N.J., March 28, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adults.
The Food and Drug Administration has approved Winrevair, Merck's (MRK) latest drug to treat pulmonary arterial hypertension, a lung condition. Investors have been anxiously awaiting the approval as the company is set to lose its patent for Keytruda. The drug will help to reduce the risk of death and worsening events in patients by 84%. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to discuss how the treatment could offer a potential path to the upside for Merck. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's Note: This article was written by Gabriel Roy
RAHWAY, N.J., March 26, 2024--FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension